mydrugindex
Kenyan Reference & Directory
Free lookups today: 0/3 · Unlimited with Pro Subscribe from KES 99
Free lookups: 0/3 Unlimited with Pro → Browse by class Interactions · Tip: type at least 2 letters, then pick a result

INN monograph

Ciprofloxacin eye drops

Fluoroquinolone antibiotic · POM

POM

Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; Professional class pharmacology (Fluoroquinolone antibiotic)

Class
Fluoroquinolone antibiotic
Schedule
POM
Route
ORAL / IV
Onset
1–2 hours oral
Duration
12–24 hours (agent-dependent)
Pregnancy
Generally avoid unless n...
Renal
Many agents need CrCl-ba...
High-alert
No

Kenya market

Wholesale / list prices where loaded

From
KES 110
Median
KES 110
Brands
8

Risk first

Contraindications

  • Hypersensitivity to quinolones.
  • History of quinolone-related tendon disorder.
  • Avoid in myasthenia gravis (exacerbation).
  • Generally avoid in children/adolescents except specific labelled indications.
  • Caution pregnancy/lactation — prefer alternatives when possible.

Precautions

  • FDA/EMA boxed risks: tendinopathy/rupture, peripheral neuropathy, CNS effects, aortic aneurysm risk in susceptible patients, QT prolongation (esp. moxifloxacin), dysglycaemia, psychiatric effects.
  • Avoid in patients with significant risk factors unless benefits outweigh risks.
  • Photosensitivity.
  • Separate from polyvalent cations (antacids, Fe, Ca, dairy, sucralfate) by several hours.

Point of care

Dosing

Adult

CORNEAL ULCERS: 2 drops every 15 minutes for the first 6 hours and then 2 drops every 30 minutes for the remainder of the first day. On the second day, instill 2 drops in the affected eye hourly. On the 3rd through the 14th day, place two drops in the affected eye every four hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred. BACTERIAL CONJUNCTIVITIS: 1-2 drops instilled into the conjunctival sac(s) every 2 hrs while awake for two days and one or two drops every four hours while awake for the next five days.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Many agents need CrCl-based adjustment (e.g. ciprofloxacin, levofloxacin).

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Hepatotoxicity uncommon but reported; moxifloxacin has more hepatic clearance.

Safety

Drug interactions

Open checker →
  • Reserve for infections where benefits outweigh class risks.
  • Prefer culture-directed therapy.
  • Counsel tendon pain stop-drug advice.
  • Check ECG risk factors if using QT-prolonging FQ.
  • Stewardship: avoid for uncomplicated cystitis/sinusitis when alternatives exist.

Safety

Adverse effects

  • White crystalline precipitates, lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival
  • hyperemia and a bad taste following instillation

Use

Indications

  • Therapeutic use is agent- and indication-specific within the class (Fluoroquinolone antibiotic).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
  • Bacterial eye infections

Pharmacology

Mode of action

Interferes with bacterial DNA synthesis by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV Fluoroquinolones inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription.

Inhibit DNA gyrase / topo IV Block replication Bactericidal
Full mechanism text

Interferes with bacterial DNA synthesis by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV Fluoroquinolones inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription. Bactericidal concentration-dependent killing with a post-antibiotic effect.

ADME

Pharmacokinetics & PD

Onset 1–2 hours oral
Duration 12–24 hours (agent-dependent)
Route ORAL / IV
Distribution including prostate and bone (agent-dependent). Renal and/or hepatic clearance varies by agent — adjust dose in organ impairment as labelled.
Full PK/PD text

Excellent oral bioavailability for most agents (near-IV for ciprofloxacin/levofloxacin in many settings). Wide tissue distribution including prostate and bone (agent-dependent). Renal and/or hepatic clearance varies by agent — adjust dose in organ impairment as labelled.

Kenya

Brands & prices

8 listed
Brand Company Pack KES
Beuflox eye/ear drops Incepta Pharma Standard Commercial Pack
Ceprolen ear/eye drops Indoco Remedies Ltd. Standard Commercial Pack
Ciloxan Alcon Pharmaceuticals Standard Commercial Pack
Ciproken eye drops Square Pharmaceuticals Ltd Standard Commercial Pack 109.65
Ivyzoxan Ivee Aqua EPZ Ltd. Standard Commercial Pack
Proloxin ATCO Laboratories (Pvt) Ltd Standard Commercial Pack
Xcipro Amanta Healthcare Standard Commercial Pack
Zoxan FDC. Ltd Standard Commercial Pack

Special populations

Pregnancy & lactation

Pregnancy

Generally avoid unless no safer alternative; animal arthropathy concerns and limited human data for many agents.

Lactation

Often avoided or used short-term with caution; check agent-specific guidance.

Diet

Food & alcohol

  • Food
  • Food

Trust

Sources & disclaimer

Source: Local active-ingredient clinical extract; Professional class pharmacology (Fluoroquinolone antibiotic)

Last reviewed: 01 Aug 2026

Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.

Kenya Verified Health Registry